Pellet

SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed to degrade β-lactam antibiotics administered intravenously, and thus prevent colon dysbiosis. Here we describe the development of the SYN-004 enteric…
Read More...

Most of the commercially available pharmaceutical products for oral administration route are marketed in the tablet dosage forms. However, compression of multiparticulate systems is a challenge for the pharmaceutical research and industry, especially if the individual unit is a coated particle, as…
Read More...

Purpose Drug X is high solubility, high permeability BCS/DCS I small molecule drug. High dose and potential pediatric indication required multiparticulate formulation with not less than 80% drug loading to achieve flexible and low quantity dosing with potential for modified release…
Read More...

The objectives of this study are the development and evaluation of modified release multi-particulate drug delivery systems containing a BCS class II drug (meloxicam), formulated as polymer-coated pellets. Inert seeds containing microcrystalline cellulose, lactose monohydrate, and…
Read More...

Written by Dr Steve Robinson | 01-Dec-2020 Excipients from different batches or vendors may be variable in quality and it is often necessary to perform pre-formulation assessment for each batch of excipient received. In some cases, excipients from different vendors require comparative assessment…
Read More...

Objective(s): Liqui-Mass technology has shown promising advantages in terms of commercial production and formulation manipulation. This study attempts to further explore the potential of enhanced drug release of effervescent Liqui-Pellet by optimizing certain parameters. Materials and Methods: In…
Read More...

This is the 4th Webinar on Multiparticulates in our series of "Multiparticulates - Modern oral drug products for our society". In this webinar Norbert Pöllinger will inform you on the basics of functional coating applications. Multiparticulates Multiparticulates such as micropellets, pellets,…
Read More...

Increasing expectations to understand material properties and process parameters impact on drug product performance resulted in increased efforts towards evaluation of drug/excipients mixtures, particularly during compression. Several research groups introduced material classification methodologies…
Read More...

Multiple-unit pellet systems (MUPS) oer many advantages over conventional solid dosage forms both for the manufacturers and patients. Coated pellets can be efficiently compressed into MUPS in classic tableting process and enable controlled release of active pharmaceutical ingredient (APIs). For…
Read More...

As the demand for pediatric dosage forms continues to increase across the industry, there can be formulation challenges for this patient population. Pediatric patients may require different dosage forms depending on age ranges, and patient compliance can be significantly impacted based on the size,…
Read More...